Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects.
Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects.
复制标题
DOI：
--
复制
发表时间：
2003-06
期刊：
影响因子：
--
通讯作者：
W. Robeson;V. Dhawan;A. Belakhlef;Yilong Ma;Von Pillai;T. Chaly;C. Margouleff;David Bjelke;D. Eidelberg
中科院分区：
文献类型：
--
作者：
W. Robeson;V. Dhawan;A. Belakhlef;Yilong Ma;Von Pillai;T. Chaly;C. Margouleff;David Bjelke;D. Eidelberg
这项未标记的研究旨在评估一种新的放射性药物N-(3-(18)F-fluoropropyl)-2beta-carbomethoxy-3beta-(4-iodophenyl)nortropane((18)F-FPCIT)在人体内的辐射剂量学。目的是确定与临床研究中公认的使用指南一致的极限剂量，并将辐射负荷与其他药物如(123)I-FPCIT、(18)F-氟多巴和(18)F-FDG进行比较。方法对6例患者进行膀胱动态PET扫描，其中2例行脑扫描，5例行胸腹部扫描。感兴趣的区域被放置在每个器官的合成图像上，其中活动被可视化，以生成时间-活动曲线。使用MIRDOSE3程序根据停留时间计算剂量。结果膀胱壁是剂量学的关键器官，剂量为0.0586+/-0.0164 mGyMBq。剂量主要(97.2%)来自膀胱内容物中的活动。该剂量低于PET中常用的任何其他评估多巴胺能功能的药物。有效剂量当量(0.0120 mGyMBq)也低于可比化合物。结论(18)F-FPCIT与其他用于多巴胺能神经功能研究的试剂相比具有良好的剂量学特性。成人患者可以给予高达853MBq(23MCI)的剂量，并保持在可接受的指南内。
UNLABELLED This study was designed to evaluate the radiation dosimetry in human subjects for a new radiopharmaceutical, N-(3-(18)F-fluoropropyl)-2beta-carbomethoxy-3beta-(4-iodophenyl)nortropane ((18)F-FPCIT). The goal was to determine a limiting dose consistent with accepted guidelines for use in clinical studies and to compare the radiation burden with other agents such as (123)I-FPCIT, (18)F-fluorodopa, and (18)F-FDG. METHODS Dynamic PET scans of the urinary bladder were obtained in 6 subjects; 2 subjects had brain scans and 5 subjects had scans of the thorax or abdomen. Regions of interest were placed over composite images of each organ for which activity was visualized to generate time-activity curves. Doses were calculated from residence times using the MIRDOSE3 program. RESULTS The critical organ for dosimetry is the urinary bladder wall with a dose of 0.0586 +/- 0.0164 mGy/MBq. The dose comes primarily (97.2%) from activity in the urinary bladder contents. The dose is lower than any of the other agents used commonly in PET to assess dopaminergic function. The effective dose equivalent (0.0120 mGy/MBq) is also lower than comparable compounds. CONCLUSION (18)F-FPCIT has favorable dosimetry when compared with other agents used to study dopaminergic function. Doses as high as 853 MBq (23 mCi) may be given to adult patients and remain within accepted guidelines.